TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06220396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization with Hemodynamics and Limited Echocardiogram
Description: Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray absorptiometry (DEXA) scan
Description: A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
Study: NCT05991700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-Dried California Table Grape
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Study: NCT06422845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolve AV Peripheral Scoring Drug-coated Balloon
Description: Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
Study: NCT05641688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
Study: NCT03847311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Study: NCT06116786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-86974680
Description: JNJ-86974680 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-86974680
Description: JNJ-86974680 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered.
Study: NCT06028438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: Certolizumab will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab
Description: Certolizumab will be administered subcutaneously.
Study: NCT05552339

Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Following the physicians' decision.

Intervention type: DRUG
Intervention: Type 2 DM drugs
Description: Following the physicians' decision
Study: NCT05078060

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Intramuscular or subcutaneous administration
Study: NCT06026982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic and pickle
Description: probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
Study: NCT05529615

Intervention type: PROCEDURE
Group type: OTHER
Intervention: detection of ctDNA
Description: the ctDNA will be detected during the treatment and served as the andomization basis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: detection of ctDNA
Description: the ctDNA will be detected during the treatment and served as the andomization basis
Study: NCT05781516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Oral Baricitinib 2mg daily for 12 months.
Study: NCT05948761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia through modified hypoxic generator
Description: Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia through hypoxic generator without active elements
Description: Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants, without active elements.
Study: NCT06014593

Intervention type: DEVICE
Group type: OTHER
Intervention: expirogram
Description: Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).

Intervention type: DEVICE
Group type: OTHER
Intervention: expirogram
Description: Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
Study: NCT06411925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atock Dry Syrup
Description: Dry syrup, TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry syrup, TID
Study: NCT04722744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: screwmented metal frameworks
Description: Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screwmented metal frameworks
Description: Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
Study: NCT04948203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Triangular-shaped tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Triangular-shaped tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Triangular-shaped tablet
Study: NCT05078060

Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: Intramuscular administration
Study: NCT04822844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Essential Oil
Description: Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger Essential Oil
Description: Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
Study: NCT05364684

Intervention type: DRUG
Group type: OTHER
Intervention: LUM-201
Description: LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
Study: NCT06213831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream 1.5%
Description: Ruxolitinib Cream 1.5%
Study: NCT06507371

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: node-sparing modified short-course radiotherapy
Description: radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx

Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study: NCT06205719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofol
Description: sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remazolam
Description: sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remazolam
Description: sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: antagonism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 2ug/kg Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 2ug/kg Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 2ug/kg Remifentanil
Study: NCT05697809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXU-001
Description: Suprachoroidal sustained release dexamethasone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXU-001
Description: Suprachoroidal sustained release dexamethasone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXU-001
Description: Suprachoroidal sustained release dexamethasone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXU-001
Description: Suprachoroidal sustained release dexamethasone acetate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated suprachoroidal illuminated microcatheter
Description: Ophthalmic administration device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated suprachoroidal illuminated microcatheter
Description: Ophthalmic administration device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated suprachoroidal illuminated microcatheter
Description: Ophthalmic administration device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated suprachoroidal illuminated microcatheter
Description: Ophthalmic administration device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex® Ophthalmic Intravitreal Implant
Description: Ophthalmic dexamethasone intravitreal implant
Study: NCT06507371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: RADIATION
Group type: OTHER
Intervention: standard short-course radiotherapy
Description: radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study: NCT04924309

Intervention type: OTHER
Intervention: Exposure: donor sperm
Description: One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
Study: NCT06094556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1826
Description: dose is calculated based on the subjects' baseline weight.
Study: NCT04611191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team Sports
Description: The intervention involves team sports in sports clubs in local municipalities
Study: NCT05183477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast track
Description: short cut for the request of xrays directly at triage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal pathway
Description: x-ray would be required according to doctor's clinical evaluation.
Study: NCT06507371

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard short-course radiotherapy
Description: radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study: NCT06120140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous (IV) infusion or SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous (IV) infusion or SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin lotion will be used as topical application on the scalp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine solution will be used as topical application on hands and feet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noncomedogenic skin moisturizer
Description: Noncomedogenic skin moisturizer will be used as topical application.
Study: NCT04208217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modeling to Learn (MTL)
Description: Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual quality improvement (QI)
Description: Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study: NCT06150157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88549968
Description: JNJ-88549968 will be administered.
Study: NCT05169190

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stellate Ganglion Block
Description: The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject.
Study: NCT04879199

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static stability measurement
Description: The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static stability measurement
Description: The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic stability measurement
Description: The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic stability measurement
Description: The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized.
Study: NCT04732208

Intervention type: DIAGNOSTIC_TEST
Intervention: Colour fundus photography
Description: Fundus images will be captured before and after administration of mydriatic agent
Study: NCT04859660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
Study: NCT05076149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-121/TEZ/D-IVA)
Description: Placebo matched to VX-121/TEZ/D-IVA for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.
Study: NCT06010901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
Study: NCT04611191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The intervention involves a control condition with participants continuing their normal way of living
Study: NCT06429345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 Milligrams Oral Capsule
Description: Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.